181 related articles for article (PubMed ID: 32996020)
21. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
22. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.
Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D
Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003
[TBL] [Abstract][Full Text] [Related]
24. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; Sisti J; John EM; Lynch CF; Brooks JD; Mellemkjær L; Boice JD; Knight JA; Concannon P; Capanu M; Tischkowitz M; Robson M; Liang X; Woods M; Conti DV; Duggan D; Shore R; Stram DO; Thomas DC; Malone KE; Bernstein L; ; Bernstein JL
J Clin Oncol; 2018 May; 36(15):1513-1520. PubMed ID: 29620998
[TBL] [Abstract][Full Text] [Related]
25. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
[TBL] [Abstract][Full Text] [Related]
26. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
[TBL] [Abstract][Full Text] [Related]
27. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies.
Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J
Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988
[TBL] [Abstract][Full Text] [Related]
28. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J
Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of germline variants in inflammatory breast cancer.
Rana HQ; Sacca R; Drogan C; Gutierrez S; Schlosnagle E; Regan MM; Speare V; LaDuca H; Dolinsky J; Garber JE; Overmoyer BA
Cancer; 2019 Jul; 125(13):2194-2202. PubMed ID: 30933323
[TBL] [Abstract][Full Text] [Related]
31. Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network.
Fan X; Wynn J; Shang N; Liu C; Fedotov A; Hallquist MLG; Buchanan AH; Williams MS; Smith ME; Hoell C; Rasmussen-Torvik LJ; Peterson JF; Wiesner GL; Murad AM; Jarvik GP; Gordon AS; Rosenthal EA; Stanaway IB; Crosslin DR; Larson EB; Leppig KA; Henrikson NB; Williams JL; Li R; Hebbring S; Weng C; Shen Y; Crew KD; Chung WK
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34377931
[TBL] [Abstract][Full Text] [Related]
32. Penetrance of male breast cancer susceptibility genes: a systematic review.
Chamseddine RS; Wang C; Yin K; Wang J; Singh P; Zhou J; Robson ME; Braun D; Hughes KS
Breast Cancer Res Treat; 2022 Jan; 191(1):31-38. PubMed ID: 34642874
[TBL] [Abstract][Full Text] [Related]
33. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
34. Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
Dong L; Wu N; Wang S; Cheng Y; Han L; Zhao J; Long X; Mu K; Li M; Wei L; Wang W; Zhang W; Cao Y; Liu J; Yu J; Hao X
Hum Mutat; 2018 Oct; 39(10):1442-1455. PubMed ID: 30039884
[TBL] [Abstract][Full Text] [Related]
35. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
36. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
37. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
[TBL] [Abstract][Full Text] [Related]
40. Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers.
Dean M; Tezak AL; Johnson S; Pierce JK; Weidner A; Clouse K; Pal T; Cragun D
Patient Educ Couns; 2021 Apr; 104(4):720-725. PubMed ID: 33455826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
